| Property | Value |
|----------|-------|
| **Symbol** | RIMS1 |
| **Name** | Regulating Synaptic Membrane Exocytosis 1 |
| **Chromosome** | 6q13 |
| **NCBI Gene ID** | 9747 |
| **OMIM** | 606410 |
| **Ensembl** | ENSG00000165371 |
| **UniProt** | Q86YW5 |
| **Protein Length** | 1,770 amino acids |
| **Molecular Weight** | ~205 kDa |
RIMS1 (Regulating Synaptic Membrane Exocytosis 1), also known as RIM1α, is a critical presynaptic active zone protein that orchestrates synaptic vesicle docking, priming, and calcium-triggered neurotransmitter release. Discovered in 1999, RIMS1 serves as a central scaffold at the presynaptic active zone, coupling voltage-gated calcium channels to synaptic vesicles and regulating the probability of release.
RIMS1 is essential for normal synaptic transmission and plasticity. Its dysfunction has been implicated in Alzheimer's disease, Parkinson's disease, epilepsy, and retinal degeneration.
¶ Gene Structure and Protein Architecture
The RIMS1 gene spans approximately 90 kb on chromosome 6q13 and comprises 32 exons. The protein contains multiple functional domains that mediate its diverse interactions:
¶ Protein Domains
- N-terminal Zinc Finger Domain: Binds to Rab3 and Rab27
- PDZ Domain: Interacts with PSD-95 and other MAGUK proteins
- C2 Domains (C2A, C2B): Bind to calcium and phospholipids
- C-terminal Proline-Rich Region: Binds to SH3 domain-containing proteins
This modular architecture enables RIMS1 to simultaneously interact with multiple presynaptic proteins, forming a critical hub for synaptic vesicle cycling.
RIMS1 is a master organizer of the presynaptic active zone:
- Recruits and scaffolds other active zone proteins including Munc13, CAPS, and ELKS
- Links voltage-gated calcium channels to synaptic vesicle release sites
- Organizes the release site geometry for optimal exocytosis
- Maintains the structural integrity of the active zone
RIMS1 is essential for synaptic vesicle priming:
- Facilitates the transition of synaptic vesicles from a docked to a releasable state
- Works in concert with Munc13 and CAPS proteins
- Controls the size of the readily releasable pool (RRP)
- Regulates the kinetics of vesicle release
RIMS1 directly couples voltage-gated calcium channels to synaptic vesicles:
- Binds to Cav2.1 (P/Q-type) and Cav2.2 (N-type) channels
- Facilitates tight coupling between calcium influx and vesicle release
- Determines release probability and timing
- Enables precise temporal control of neurotransmitter release
RIMS1 interacts with Rab3 GTPases to regulate vesicle cycling:
- Binds to Rab3 on synaptic vesicles in a GTP-dependent manner
- Coordinates vesicle docking and priming with Rab3 cycling
- Regulates the size and replenishment of synaptic vesicle pools
- Links vesicle trafficking to release site availability
RIMS1 dysfunction contributes to synaptic failure in Alzheimer's disease:
Molecular Findings:
- Reduced RIMS1 protein levels in AD brain, particularly in hippocampus
- Impaired coupling of calcium channels to release sites
- Decreased synaptic vesicle priming and release probability
- Altered interaction with amyloid-beta and tau pathology
Mechanistic Links:
- Amyloid-beta oligomers reduce RIMS1 expression and function
- Tau pathology disrupts RIMS1 localization at active zones
- Synaptic RIMS1 loss correlates with cognitive decline
- Impaired long-term potentiation (LTP) due to RIMS1 dysfunction
Therapeutic Implications:
- Small molecules that enhance RIMS1 expression or function
- Gene therapy approaches to restore synaptic transmission
- RIMS1 as a biomarker for synaptic health in AD
RIMS1 plays a crucial role in dopaminergic signaling in Parkinson's disease:
Dopaminergic Vesicle Release:
- RIMS1 regulates vesicular dopamine release in substantia nigra neurons
- Altered RIMS1 expression in PD brain
- Impaired coupling of Cav2 channels to vesicle release
- Reduced release probability in dopaminergic terminals
Molecular Mechanisms:
- Alpha-synuclein aggregation affects RIMS1 function
- LRRK2 mutations alter RIMS1-mediated signaling
- Mitochondrial dysfunction impacts RIMS1 expression
- Neuroinflammation reduces RIMS1 levels
Therapeutic Strategies:
- RIMS1-enhancing compounds for dopaminergic protection
- Modulation of presynaptic function to restore dopamine release
Dominant RIMS1 mutations cause epileptic encephalopathy:
Clinical Features:
- Early-onset seizures (infantile or childhood onset)
- Developmental delay and intellectual disability
- Autistic features in some patients
- Variable severity based on mutation type
Pathogenic Mechanisms:
- Hyperomorphic mutations increase release probability
- Disrupted short-term plasticity
- Imbalanced excitation/inhibition
- Altered calcium channel coupling
RIMS1 mutations cause autosomal dominant retinal degeneration:
- Progressive loss of cone and rod photoreceptor function
- Reduced visual acuity and color vision defects
- Night blindness in early stages
- Photoreceptor synaptic dysfunction
Molecular Basis:
- RIMS1 is essential for ribbon synapse function in photoreceptors
- Required for rapid, sustained neurotransmitter release
- Mutations disrupt vesicle priming at ribbon synapses
- RIMS1 variants associated with non-syndromic ID
- Impaired synaptic plasticity and learning
- Variable expressivity and incomplete penetrance
RIMS1 forms an extensive presynaptic interactome:
| Partner |
Interaction Domain |
Function |
| Rab3/Rab27 |
N-terminal zinc finger |
Vesicle cycling |
| Munc13 |
PDZ domain |
Priming organization |
| CAPS |
C2 domains |
Priming coordination |
| Cav2.1/Cav2.2 |
C2A domain |
Calcium coupling |
| ELKS |
PDZ domain |
Active zone scaffold |
| Liprin-α |
Proline-rich region |
Active zone assembly |
| CAST/ELKS2 |
PDZ domain |
Active zone organization |
RIMS1 integrates multiple presynaptic signaling cascades:
- Calcium Signaling: Direct coupling to voltage-gated calcium channels
- cAMP/PKA Pathway: Regulates RIMS1 phosphorylation and function
- Rab GTPase Cycle: Coordinates vesicle cycling
- Synaptic Activity: Activity-dependent regulation of RIMS1
RIMS1 activity is regulated by:
- Phosphorylation: PKA and CaMKII phosphorylate RIMS1
- Palmitoylation: Regulates membrane association
- Ubiquitination: Controls protein stability
RIMS1 is essential for multiple forms of synaptic plasticity:
- Facilitation: RIMS1 contributes to frequency-dependent facilitation
- Depression: Controls vesicle pool replenishment
- Augmentation: Regulates sustained release during high-frequency activity
- LTP: Required for LTP induction and maintenance
- LTD: Modulates AMPA receptor internalization
- Homeostatic Plasticity: Participates in synaptic scaling responses
RIMS1 is expressed throughout the nervous system:
- Cerebral Cortex: Pyramidal neurons (layers 2/3, 5)
- Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells
- Cerebellum: Purkinje cells
- Striatum: Medium spiny neurons
- Substantia Nigra: Dopaminergic neurons
- Retina: Photoreceptor cells, bipolar cells
- Inner Ear: Hair cells
| Approach |
Target |
Status |
Notes |
| PKA modulators |
RIMS1 phosphorylation |
Research |
Enhance RIMS1 function |
| Calcium channel enhancers |
Cav2 channels |
Research |
Improve coupling |
| cAMP elevators |
PKA pathway |
Research |
Increase release probability |
- AAV-mediated RIMS1 delivery for synaptic repair
- CRISPR approaches to correct pathogenic mutations
- siRNA for allele-specific knockdown in epilepsy
- Stem cell therapy for retinal degeneration
- iPSC-derived neurons from RIMS1 mutation carriers
RIMS1 knockout mice exhibit:
- Profound deficits in synaptic vesicle priming
- Reduced spontaneous and evoked release
- Impaired LTP and learning deficits
- Retinal dysfunction
¶ Transgenic and Knock-in Models
- Conditional knockouts reveal region-specific functions
- Human mutations introduced to study disease mechanisms
- Rescue experiments demonstrate RIMS1 sufficiency
¶ Biomarkers and Diagnostics
- Clinical testing: Available for epilepsy and retinal dystrophy
- Variant interpretation: Missense and loss-of-function mutations
- Family testing: Important for genetic counseling
- RIMS1 in cerebrospinal fluid as synaptic marker
- Phosphorylated RIMS1 as activity marker
- Soluble RIMS1 in neurodegenerative disease
Key research priorities include:
- RIMS1-targeted therapeutics: Small molecules for clinical development
- Gene therapy: Safe delivery to brain and retina
- Biomarkers: RIMS1 as marker of synaptic health
- Mechanism studies: Elucidate RIMS1 dysfunction in neurodegeneration